Compare CRBU & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBU | XYF |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.4M | 186.4M |
| IPO Year | 2021 | 2018 |
| Metric | CRBU | XYF |
|---|---|---|
| Price | $2.38 | $4.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 135.5K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | ★ 11.34% |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | ★ N/A | $0.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $3.30 |
| 52 Week High | $3.53 | $20.36 |
| Indicator | CRBU | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 51.40 |
| Support Level | $1.75 | $4.37 |
| Resistance Level | $2.97 | $5.12 |
| Average True Range (ATR) | 0.17 | 0.35 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 90.48 | 71.50 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.